FDA Proactive Stance Toward Drug Development Urged By Consumer Reps
This article was originally published in The Tan Sheet
Executive Summary
Despite recent improvements, heightened agency communication and transparency are needed in the development of drugs and other health-related matters, consumer advocates told FDA staffers at the agency's Roundtable on Consumer Protection Priorities in Washington, D.C., Dec. 13.